Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

57.77 -0.84 (-1.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,455,126
Open 58.86
Bid (Size) 56.56 (1)
Ask (Size) 58.97 (1)
Prev. Close 58.61
Today's Range 57.66 - 58.86
52wk Range 57.66 - 86.29
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
From Incyte
Via Business Wire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat

Performance

YTD
-27.38%
-27.38%
1 Month
-11.46%
-11.46%
3 Month
-7.20%
-7.20%
6 Month
-20.06%
-20.06%
1 Year
-13.27%
-13.27%

More News

Read More
Expert Ratings for Incyte
Via Benzinga
3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall
Via InvestorPlace
Pancreatic Cancer Battle Boosted by $200M VC Firm
Via FinancialNewsMedia
Topics Death
Exposures Death
Analyst Ratings for Incyte
Via Benzinga
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison
Via Benzinga
Exposures Product Safety
Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival
Via Investor's Business Daily
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Incyte's Jakafi Patent Expiry In 2028 Poses Challenge, Analyst Says New Treatments To Battle For Market Share
Via Benzinga
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte Corporation
Via Business Wire
Incyte's Earnings Outlook
Via Benzinga
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
From Incyte
Via Business Wire
Cathie Wood's Ark Invest Buys Spotify, Iridium Shares — Trims Tesla, Coinbase Holdings
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2023
Via Benzinga
Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End
Via Benzinga
'I Don't Want You To Touch That': Cramer Rejects Stock Down 32% Over Past Month, Prefers Tesla
Via Benzinga
Incyte Skin Disease Drug Meets Primary Goal In Late-Stage Study In Children
Via Benzinga
Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
From Incyte
Via Business Wire
Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape
Via Benzinga
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
2 Low-Priced Stocks That Could Make You Richer
Via The Motley Fool
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
Via Talk Markets
Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.